ENXTBR:ARGX
ENXTBR:ARGXBiotechs

How Positive ADAPT SERON Results at argenx (ENXTBR:ARGX) Have Changed Its Investment Story

argenx SE recently announced positive topline results from the pivotal ADAPT SERON study, showing that VYVGART® achieved statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living for AChR-Ab seronegative gMG patients compared to placebo. This marks a potential milestone as the company prepares to seek FDA approval for expanded labeling, which could allow VYVGART to be used across all adult seronegative gMG patient subtypes for the first...